1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- Biocon Ltd.
- Novartis AG
- Pfizer Inc.
- Zydus Cadila
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The strong prevalence of oncology indications is one of the key factors expected to trigger market growth during the forecast period. Vendors are conducting studies on target specific drugs to meet the gap between the demand and supply of these therapies. Factors including the increasing geriatric population and changes in lifestyle have also contributed to the oncology indications, in turn, contributing to the mTOR Inhibitors market growth during the forecast period. Analysts have predicted that the mTOR inhibitors market will register a CAGR of over 3% by 2023.
Market Overview
Introduction of novel drug delivery systems and combination therapies
Chemotherapeutic drugs are mostly administered through conventional methods to treat different tumors. And, it is observed that the API does not reach the targeted site in appropriate quantities, thus lowering the performance of the drugs.
Adverse effects of available therapeutics
Despite being highly efficacious, mTOR inhibitors used for treating various oncology indications are associated with a spectrum of side effects. These side effects hinder patient adherence to the treatment, which poses a challenge to market growth.
Competitive Landscape
The market appears to be concentrated and with the presence of few companies including Biocon Ltd. and Intas Pharmaceuticals Ltd., the competitive environment is quite intense. Various international and national organizations are focusing on conducting programs to increase awareness about cancer and help early diagnosis of the disease. Novartis AG, Pfizer Inc., and Zydus Cadila. are some of the major companies covered in this report.
Market Overview
Introduction of novel drug delivery systems and combination therapies
Chemotherapeutic drugs are mostly administered through conventional methods to treat different tumors. And, it is observed that the API does not reach the targeted site in appropriate quantities, thus lowering the performance of the drugs.
Adverse effects of available therapeutics
Despite being highly efficacious, mTOR inhibitors used for treating various oncology indications are associated with a spectrum of side effects. These side effects hinder patient adherence to the treatment, which poses a challenge to market growth.
Competitive Landscape
The market appears to be concentrated and with the presence of few companies including Biocon Ltd. and Intas Pharmaceuticals Ltd., the competitive environment is quite intense. Various international and national organizations are focusing on conducting programs to increase awareness about cancer and help early diagnosis of the disease. Novartis AG, Pfizer Inc., and Zydus Cadila. are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Biocon Ltd.
- Novartis AG
- Pfizer Inc.
- Zydus Cadila
PART 01: EXECUTIVE SUMMARYPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORKPART 11: MARKET TRENDSPART 15: EXPLORE
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY ROA
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits:
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Biocon Ltd.
- Novartis AG
- Pfizer Inc.
- Zydus Cadila
The analyst recognizes the following companies as the key players in the global mTOR inhibitors market: Biocon Ltd., Intas Pharmaceuticals Ltd., Novartis AG, Pfizer Inc., and Zydus Cadila.
Commenting on the report, an analyst from the team said: “The latest trend gaining momentum in the market is the presence of patient assistance programs.”
According to the report, one of the major drivers for this market is the high target affinity and specificity of mTOR inhibitors.
Further, the report states that one of the major factors hindering the growth of this market is the adverse effects of available therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the team said: “The latest trend gaining momentum in the market is the presence of patient assistance programs.”
According to the report, one of the major drivers for this market is the high target affinity and specificity of mTOR inhibitors.
Further, the report states that one of the major factors hindering the growth of this market is the adverse effects of available therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Biocon Ltd.
- Intas Pharmaceuticals Ltd.
- Novartis AG
- Pfizer Inc.
- Zydus Cadila
Note: Product cover images may vary from those shown
